ALZN — Alzamend Neuro, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1677077 ·
Last close
$1.73
Market Cap
$8.35M
52W High
$2.68
52W Low
$0.84
ADV30
127,009
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jul 2026 | 0 | — | -3,025,396 | -3,027,002 | 8,542,061 | 7,591,444 | 2,739,381 |
| Apr 2026 | 0 | — | -2,870,877 | -2,869,949 | 2,079,363 | 710,689 | 1,346,152 |
| Jan 2026 | 0 | — | -2,197,654 | -2,198,991 | 4,041,833 | 2,713,139 | 1,857,328 |
| Oct 2025 | 0 | — | -998,109 | -1,000,758 | 5,091,684 | 4,449,433 | 717,488 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-6,843,544
Investing CF
$0
Financing CF
$8,814,116
CapEx
$-210,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.84
As of
2026-09-13
Balance + Analyst (yfinance extras)
Retained Earnings
$-70,334,645
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-9,090,559
Pretax Income TTM
$-9,096,700
Interest Exp TTM
$6,141
Analysts
1
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Apr 2026 | 0 | -8,766,841 | -8,772,382 | 2,079,363 | 1,346,152 | 733,211 | -8,067,813 |
| Apr 2025 | 0 | -4,496,824 | -4,514,853 | 4,602,983 | 634,761 | 3,968,222 | -6,568,186 |
| Apr 2024 | 0 | -9,937,645 | -9,947,746 | 631,588 | 3,225,773 | -2,594,185 | -8,269,993 |
| Apr 2023 | 0 | -14,870,466 | -14,878,167 | 5,915,625 | 2,870,122 | 3,045,503 | -8,923,152 |
| Apr 2022 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.87
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LNAI | Lunai Bioworks Inc. | $8.43M | $1.86 | — |
| SNGX | SOLIGENIX, INC. | $8.21M | $0.38 | — |
| XCUR | EXICURE, INC. | $8.08M | $1.24 | — |
| KALA | KALA BIO, Inc. | $8.71M | $0.45 | — |
| LGVN | Longeveron Inc. | $8.00M | $2.63 | — |
News headlines (Yahoo Finance, 1h cache)
Alzamend Neuro Regains Compliance with Nasdaq Listing Standards
2026-09-16 12:00 · Yahoo
Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC
2026-08-20 12:00 · Yahoo
Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending
2026-08-04 12:00 · Yahoo
Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital
2026-04-07 12:00 · Yahoo
Is Centene (CNC) Stock Outpacing Its Medical Peers This Year?
2026-09-22 13:40 · Yahoo
Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain
2026-08-18 12:00 · Yahoo
Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured
2026-03-26 12:00 · Yahoo
Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital
2026-03-16 12:00 · Yahoo
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?
2026-01-26 14:40 · Yahoo
EMBC Q4 Preview: Product Momentum and Strategy Gains to Support Growth?
2025-11-20 12:50 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.